继此前将核心自免产品泰它西普的海外权益授权给Vor Bio后,荣昌生物(688331.SH;09995.HK)再次达成一项BD(商务拓展)交易。 8月19日开盘前,荣昌生物公告与日本参天制药株式会社(下称“参天制药”)全资子公司参天制药(中国)有限公司(下称“参天中国”)达成协议,将具有自主知识产权的RC28-E注射液有偿许可给参天中国。 根据协议内容,参天中国将获得RC28-E在大中华区及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.